ZA984633B - Treatment of schizophrenia and psychosis - Google Patents

Treatment of schizophrenia and psychosis

Info

Publication number
ZA984633B
ZA984633B ZA984633A ZA984633A ZA984633B ZA 984633 B ZA984633 B ZA 984633B ZA 984633 A ZA984633 A ZA 984633A ZA 984633 A ZA984633 A ZA 984633A ZA 984633 B ZA984633 B ZA 984633B
Authority
ZA
South Africa
Prior art keywords
psychosis
schizophrenia
treatment
diseases
methylpyridine
Prior art date
Application number
ZA984633A
Other languages
English (en)
Inventor
Frank Sams-Dodd
Jorn Arnt
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ZA984633B publication Critical patent/ZA984633B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA984633A 1997-05-29 1998-05-29 Treatment of schizophrenia and psychosis ZA984633B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK62097 1997-05-29

Publications (1)

Publication Number Publication Date
ZA984633B true ZA984633B (en) 1998-12-11

Family

ID=8095640

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA984633A ZA984633B (en) 1997-05-29 1998-05-29 Treatment of schizophrenia and psychosis

Country Status (10)

Country Link
US (1) US6297262B1 (enExample)
EP (1) EP1014974B1 (enExample)
JP (1) JP2002500651A (enExample)
AT (1) ATE273007T1 (enExample)
AU (1) AU7639598A (enExample)
DE (1) DE69825605T2 (enExample)
ES (1) ES2227836T3 (enExample)
PT (1) PT1014974E (enExample)
WO (1) WO1998053820A1 (enExample)
ZA (1) ZA984633B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
ES2660765T3 (es) 2004-06-21 2018-03-26 The Board Of Trustees Of The Leland Stanford Junior University Genes y rutas expresadas de forma diferencial en trastorno bipolar y/o trastorno depresivo mayor
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2564864B8 (en) 2005-11-12 2015-05-13 The Board of Trustees of The Leland Stanford Junior University FGF2-related methods for diagnosing and treating depression
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2013184824A1 (en) 2012-06-05 2013-12-12 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
WO2017147104A1 (en) * 2016-02-24 2017-08-31 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combinations
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE845612A (fr) 1976-03-23 1977-02-28 Derives de tetrazole-5-carboxamide et leur preparation
DE3421072A1 (de) 1984-06-06 1985-12-12 Heinrich Mack Nachf., 7918 Illertissen 1,4:3,6-dianhydro-hexit-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0261763B1 (en) 1986-06-27 1994-02-09 Beecham Group Plc Novel bridged bicyclic N-heterocycles
IL83275A (en) 1986-09-08 1994-02-27 Novo Nordisk As Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US5405853A (en) 1987-09-10 1995-04-11 Merck Sharpe & Dohme Ltd. Thiadiazoles useful in the treatment of senile dementia
US5328925A (en) 1989-02-22 1994-07-12 Novo Nordisk A/S Piperidine compounds and their use
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5073560A (en) 1990-07-20 1991-12-17 Fisons Corporation Spiro-isoxazolidine derivatives as cholinergic agents
IE922270A1 (en) 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US5330994A (en) 1992-03-24 1994-07-19 Warner-Lambert Company Tetrahydropyridine isoxazoline derivatives
EP0659078B1 (en) 1992-08-31 2003-01-15 University Of Florida Research Foundation, Inc. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
CZ181493A3 (en) 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
PT734259E (pt) * 1993-08-19 2002-11-29 Novo Nordisk As Utilizacao de derivados de piperidina para o tratamento da esquizofrenia
US5705512A (en) 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5691365A (en) 1995-07-18 1997-11-25 University Of Kentucky Research Foundation Nicotinic receptor antagonists in the treatment of neuropharmacological disorders
US5756501A (en) 1995-12-13 1998-05-26 American Home Products Corporation Saturated and unsaturated pyridazino 4,5-B! indolizines useful as antidementia agents
US5739119A (en) 1996-11-15 1998-04-14 Galli; Rachel L. Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA

Also Published As

Publication number Publication date
DE69825605D1 (de) 2004-09-16
ATE273007T1 (de) 2004-08-15
EP1014974B1 (en) 2004-08-11
ES2227836T3 (es) 2005-04-01
US6297262B1 (en) 2001-10-02
JP2002500651A (ja) 2002-01-08
WO1998053820A1 (en) 1998-12-03
DE69825605T2 (de) 2005-09-15
PT1014974E (pt) 2004-12-31
EP1014974A1 (en) 2000-07-05
AU7639598A (en) 1998-12-30

Similar Documents

Publication Publication Date Title
AU7639598A (en) Treatment of schizophrenia and psychosis
TW249226B (enExample)
NO900439L (no) Fremgangsmaate for behandling av uorganisk pulver.
NO913765D0 (no) Fremgangsmaate for kontinuerlig fremstilling av tyggegummi.
NO911934D0 (no) Fremgangsmaate for fremstilling av bicykliske 1-aza-cykloalkaner.
FI913017A7 (fi) Menetelmä antianginaalisten 5-(2-alkoksi-5-piperidinyyli- ja -piperatsinyylisulfonyylifenyyli)-1,6-dihydro-7H-pyratsolo/4,3-d/pyrimidin-7-onien valmistamiseksi ja välituotteita
AU6801694A (en) The treatment of small animals
NO944871D0 (no) Fremgangsmåte for fremstilling av polydimetylsiloksaner
NO953254D0 (no) Substituerte azolonderivater for behandling av sykdommer forårsaket av helikobakter
EP0467564A3 (en) Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
FI941776A0 (fi) Menetelmä 1,2,4-tiadiatsolien valmistamiseksi
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU3187595A (en) Compounds for the treatment of restenosis
EP0424156A3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
AU4712696A (en) The use of heterocyclic compounds
ZA929879B (en) Compositions for the treatment of mammalian diseases.
AU639322B2 (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
AU4081393A (en) Medicaments for the treatment of anxiety
ITRM950484A0 (it) Impiego dell'amtolmetineguacil (med 15) come farmaco antisecretivo sulla gastrica e quindi gastroprotettivo.
NO931839L (no) Fremgangsm}te for fremstilling av pergolid
SI0778025T1 (en) Use of 8,9-dehydroestrone for the manufacture of a medicament for the treatment of diseases caused by free radicals
AU5018893A (en) Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
IT1296613B1 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.
IL117465A (en) Use of certain cystine derivatives for the preparation of a medicament for the treatment of restenosis